Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone

By Y. Sato, K. Murase, J. Kato, M. Kobune, Tsutomu Sato, Y. Kawano, R. Takimoto, Kouichi Takada, K. Miyanishi, T. Matsunaga and 2 more. Nature Biotechnology, 2008

603 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ff67010e73ac2be6d7def623a88097112399c7ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Natascha Roehlen
2. E. Crouchet
3. T. Baumert
4. S. Friedman
5. Y. Saiman
6. J. Puche
7. J. Bonner

In Hepatology

1. T. Baumert
2. Natascha Roehlen
3. E. Crouchet
4. S. Friedman
5. Y. Saiman
6. J. Puche
7. J. Bonner

In Molecular Biology

1. N. Bertrand
2. Xiaoyang Xu
3. S. Mitragotri
4. O. Farokhzad
5. S. Friedman
6. Eric M. Pridgen
7. D. Tuveson
8. Xue-Qing Zhang

Citations in the corpus

• Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. (2016, neutral): “2 ± 32 nm n/a LI90 cells (human HS cell line), dimethylnitro samine (DMN) treated Male SpragueDawley rats [51]”
• The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “Scavenging receptors can serve to target Kupffer and endothelial cells [158,159], while coupling vitamin A on the surface of CDCs revealed an effective way of delivering actives to stellate (Ito) cells that play a fundamental role in liver fibrosis [160].”
• Evolving challenges in hepatic fibrosis (2010, background): “Moreover, exciting prospects for targeting diagnostic agents or therapies directly to HSCs may enhance efforts to improve both the diagnosis and treatment of hepatic fibrosis”
• The promises and pitfalls of RNA-interference-based therapeutics (2009, neutral): “A different conjugation of an siRNA to vitamin-A-coupled liposomes succeeded in delivering antifibrotic siRNAs to hepatic stellate cells, which are produced in response to liver damag”
• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “Similarly, the retinol-binding protein, which is constitutively expressed in the brain, the spleen, the eyes, the genital organs and in lower quantities in the heart and lungs, was recently exploited to target stellate cells in the liver to alleviate cirrhotic fibrosis [88, 89].”
• Nanoparticles in the clinic (2016, background): “Other examples include Vitamin A conjugation to liposomes (ND-L02-s0201) to target delivery of siRNA to stellate cells in the liver to treat hepatic fibrosis.(83) A HER-2 targeted PEGylated liposomal doxorubicin (MM-302) for treatment of breast cancer is also being developed.”
• The Pancreas Cancer Microenvironment (2012, background): “may be gleaned through investigation of pathways known tobe relevant forhepatic stellate cell activation (39).”
• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “Significant anti-fibrotic effects in 3 and in-vivo models of liver fibrosis [315].”